Non-infectious pulmonary toxicity of rituximab: A systematic review

Rheumatology

Volumn 51, Issue 4, 2012, Pages 653-662

  Hadjinicolaou, Andreas V ^a   Nisar, Muhammad K ^a   Parfrey, Helen ^b   Chilvers, Edwin R ^b   östör, Andrew J K ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Biologics; Lung disease; Rheumatoid arthritis; Rituximab; Treatment

Indexed keywords

RITUXIMAB;

AGE; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ATELECTASIS; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLUBBING FINGERS; CONTINUOUS INFUSION; COUGHING; DISEASE COURSE; DRUG INDICATION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEVER; FIBROSING ALVEOLITIS; FOCAL GLOMERULOSCLEROSIS; FOLLICULAR LYMPHOMA; GRAFT VERSUS HOST REACTION; HEMOPTYSIS; HISTIOCYTOSIS; HODGKIN DISEASE; HUMAN; HYPOXEMIA; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INTERSTITIAL PNEUMONIA; KIDNEY ALLOGRAFT REJECTION; LARGE CELL LYMPHOMA; LUNG ALVEOLITIS; LUNG DIFFUSION CAPACITY; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG INFILTRATE; LUNG TOXICITY; MANTLE CELL LYMPHOMA; MONOTHERAPY; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; MULTIPLE CYCLE TREATMENT; NONINFECTIOUS PULMONARY TOXICITY; ONSET AGE; ORGANIZING PNEUMONIA; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; SEX DIFFERENCE; SIDE EFFECT; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THORAX PAIN; THORAX RADIOGRAPHY; THROMBOSIS; TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; WHEEZING;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LUNG DISEASES, INTERSTITIAL; TIME FACTORS;

EID: 84858693051     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker290     Document Type: Article

References (97)

1. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
2. Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94.
3. Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 2003;62(Suppl. 2):ii55-9.
4. Sibilia J, Gottenberg JE, Mariette X. Rituximab: a new therapeutic alternative in rheumatoid arthritis. Joint Bone Spine 2008;75:526-32.
5. Genentech. Rituxan: highlights of prescribing information (revised), 2008, http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf (2 September 2011, date last accessed).
6. Ostor AJ, Chilvers ER, Somerville MF et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006;33:622-8.
7. Alexandrescu DT, Dutcher JP, O'Boyle K et al. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004;45: 2321-5.
8. Biehn SE, Kirk D, Rivera MP et al. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma. Hematol Oncol 2006;24:234-7.
9. Bitzan M, Anselmo M, Carpineta L. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. Pediatr Pulmonol 2009;44:922-34.
10. Brusamolino E, Rusconi C, Montalbetti L et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006;91: 496-502.
11. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-1.
12. Byrd JC, Peterson BL, Morrison VA et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003;101:6-14.
13. Chaumais MC, Garnier A, Chalard F et al. Fatal pulmonary fibrosis after rituximab administration. Pediatr Nephrol 2009;24:1753-5.
14. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97: 101-6.
15. Davis TA, White CA, Grillo-Lopez AJ et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999;17:1851-7.
16. Disel U, Paydas S, Yavuz S et al. Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab. Chemotherapy 2010;56:89-93.
17. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350: 2572-81.
18. Emery P, Fleischmann R, Filipowicz-Sosnowska A et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400.
19. Emmanouilides C, Territo M, Menco H et al. Mitoxantrone-cyclophosphamide-rituximab: an effective and safe combination for indolent NHL. Hematol Oncol 2003;21:99-108.
20. Ennishi D, Terui Y, Yokoyama M et al. Increased incidence of interstitial pneumonia by CHOP combined with rituximab. Int J Hematol 2008;87:393-7.
21. Feenstra JF, Hickey BP, Blackwell EA. Acute respiratory failure associated with cladribine pneumonitis. Intern Med J 2004;34:583-4.
22. Ghesquieres H. Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy. Ann Oncol 2005;16:1399.
23. Hainsworth JD, Litchy S, Barton JH et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21: 1746-51.
24. Heresi GA, Farver CF, Stoller JK. Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab: case report and review of the literature. Respiration 2008; 76:449-53.
25. Herishanu Y, Polliack A, Leider-Trejo L et al. Fatal interstitial pneumonitis related to rituximab-containing regimen. Clin Lymphoma Myeloma 2006;6:407-9.
26. Hiraga J, Kondoh Y, Taniguchi H et al. A case of interstitial pneumonia induced by rituximab therapy. Int J Hematol 2005;81:169-70.
27. Jullien V, Perrin C, Peyrade F et al. [Alveolar hypoxemic interstitial pneumonia related to rituximab therapy]. Rev Mal Respir 2004;21:407-10.
28. Kanelli S, Ansell SM, Habermann TM et al. Rituximab toxicity in patients with peripheral blood malignant B-cell lymphocytosis. Leuk Lymphoma 2001;42:1329-37.
29. Katsuya H, Suzumiya J, Sasaki H et al. Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:1818-23.
30. Kazama T, Faria SC, Uchida Y et al. Pulmonary drug toxicity: FDG-PET findings in patients with lymphoma. Ann Nucl Med 2008;22:111-4.
31. Kemming JL, van Zeeland RE, Ullmann EF et al. [Interstitial pneumonitis as a side effect of rituximab]. Ned Tijdschr Geneeskd 2009;153:A526.
32. Kim KM, Kim HC, Jeon KN et al. Rituximab-CHOP induced interstitial pneumonitis in patients with disseminated extranodal marginal zone B cell lymphoma. Yonsei Med J 2008;49:155-8.
33. Kishi J, Nanki T, Watanabe K et al. A case of rituximabinduced interstitial pneumonitis observed in systemic lupus erythematosus. Rheumatology 2009;48:447-8.
34. Lee Y, Kyung SY, Choi SJ et al. Two cases of interstitial pneumonitis caused by rituximab therapy. Korean J Intern Med 2006;21:183-6.
35. Leon RJ, Gonsalvo A, Salas R et al. Rituximab-induced acute pulmonary fibrosis. Mayo Clin Proc 2004;79:949, 953.
36. Lim KH, Yoon HI, Kang YA et al. Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. Korean J Intern Med 2010;25:86-92.
37. Lim LC, Koh LP, Tan P. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. J Clin Oncol 1999;17:1962-63.
38. Liote H, Liote F, Seroussi B et al. Rituximab-induced lung disease: a systematic literature review. Eur Respir J 2010; 35:681-7.
39. Liu X, Hong XN, Gu YJ et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma. Leuk Lymphoma 2008;49:1778-83.
40. Macartney C, Burke E, Elborn S et al. Bronchiolitis obliterans organizing pneumonia in a patient with non-Hodgkin's lymphoma following R-CHOP and pegylated filgrastim. Leuk Lymphoma 2005;46:1523-6.
41. Maeng CH, Chin SO, Yang BH et al. A case of organizing pneumonia associated with rituximab. Cancer Res Treat 2007;39:88-91.
42. Mian M, Rass C, Hutarew G et al. Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. Leuk Lymphoma 2006;47:1683-5.
43. Montero AJ, McCarthy JJ, Chen G et al. Acute respiratory distress syndrome after rituximab infusion. Int J Hematol 2005;82:324-6.
44. Motl SE, Baskin RC. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review. Pharmacotherapy 2005;25:1151-5.
45. Nieuwenhuizen L, Verzijlbergen FJ, Wiltink E et al. A possible role of 18F-FDG positron-emission tomography scanning in the early detection of rituximab-induced pneumonitis in patients with non-Hodgkin's lymphoma. Haematologica 2008;93:1267-9.
46. Saito B, Nakamaki T, Adachi D et al. Acute respiratory distress syndrome during the third infusion of rituximab in a patient with follicular lymphoma. Int J Hematol 2004;80: 164-67.
47. Soubrier M, Jeannin G, Kemeny JL et al. Organizing pneumonia after rituximab therapy: two cases. Joint Bone Spine 2008;75:362-5.
48. Swords R, Power D, Fay M et al. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-4.
49. Tanaka Y, Yamamoto K, Takeuchi T et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17:191-7.
50. Tonelli AR, Lottenberg R, Allan RW et al. Rituximab-induced hypersensitivity pneumonitis. Respiration 2009;78:225-9.
51. Vulsteke C, Dierickx D, Verbeken E et al. Rituximab-induced fatal interstitial pneumonitis: case report. Leuk Lymphoma 2010;51:546-8.
52. Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-9.
53. Walewski J, Kraszewska E, Mioduszewska O et al. Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol 2001;18:141-8.
54. Wu SJ, Chou WC, Ko BS et al. Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007;92:141-2.
55. Yamane T, Daimaru O, Ito S et al. Drug-induced pneumonitis detected earlier by 18F-FDG-PET than by high-resolution CT: a case report with non-Hodgkin's lymphoma. Ann Nucl Med 2008;22:719-22.
56. Zerga MCL, Cicco J, Constantini P, De Riz M et al. Desquamative alveolitis: an unusual complication of treatment with mabthera. Blood 1999; 94(Suppl. 1):271.
57. Kalkanis D, Stefanovic A, Paes F et al. [18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy. Leuk Lymphoma 2009;50:904-11.
58. Leonard JP, Schuster SJ, Emmanouilides C et al. Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714-23.
59. Fehr T, Rusi B, Fischer A et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009;87: 1837-41.
60. Okamoto M, Okano A, Akamatsu S et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia 2006;20:172-3.
61. Bunworasate U, Chalermskulrat W, Chavit C et al. Interstitial pneumonitis: an unusual complication of rituximab. Chula Med J 2006;50:249-57.
62. Choi YJ, Jung WJ, Oh SI et al. A case of interstitial lung diseasec caused by rituximab in non-Hodgkin lymphoma. Korean J Med 2006;71:449-55.
63. Furie R, Looney RJ, Rovin B et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract]. Arthritis Rheum 2009;60(Suppl. 10):1149.
64. Gray ND, Brath LK. Fatal diffuse alveolar damage related to rituximab. Chest 2007;132:724S.
65. Lee DM, Oh SY, Yoon HA et al. Rituximab-induced interstitial pneumonitis in a young patient: a case report and review of the literature. Korean J Hematol 2007;42:423-7.
66. Protopapadakis C, Antoniou KM, Voloudaki A et al. Rituximab-induced nonspecific interstitial pneumonia like reaction in a patient with idiopathic thrombocytopenic purpura. Respir Med CME 2009;2:176-8.
67. Alcantara C, Gomes MJ, Ferreira C. Rituximab therapy in primary Sjogren's syndrome. Ann N Y Acad Sci 2009; 1173:701-5.
68. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205-11.
69. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006;6:394-403.
70. Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006;20:915-28.
71. Friedberg JW. Developing new monoclonal antibodies for aggressive lymphoma: a challenging road in the rituximab era. Clin Cancer Res 2004;10:5297-8.
72. Friedberg JW, Kim H, McCauley M et al. Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood 2005;105: 489-95.
73. Furst DE, Breedveld FC, Kalden JR et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis 2006; 65(Suppl. 3):iii2-15.
74. Goldblatt F, Isenberg DA. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb Exp Pharmacol 2008;181:163-81.
75. Lateef A, Lahiri M, Teng GG et al. Use of rituximab in the treatment of refractory systemic lupus erythematosus: Singapore experience. Lupus 2010;19:765-70.
76. Lateef A, Petri M. Biologics in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:504-9.
77. Meijer JM, Pijpe J, Vissink A et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009; 68:284-5.
78. Oristrell J, Bejarano G, Jordana R et al. Effectiveness of rituximab in severe Wegener's granulomatosis: report of two cases and review of the literature. Open Respir Med J 2009;3:94-9.
79. Penalver FJ, Alvarez-Larran A, Diez-Martin JL et al. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol 2010;89:1073-80.
80. Sanz I. Indications of rituximab in autoimmune diseases. Drug Discov Today Ther Strateg 2009;6:13-9.
81. Sanz I, Lee FE. B cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010;6:326-37.
82. Terrier B, Amoura Z, Ravaud P et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62: 2458-66.
83. Terrier B, Launay D, Kaplanski G et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res 2010;62:1787-95.
84. Walsh M, Jayne D. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future. Kidney Int 2007;72:676-82.
85. Zapata LF, Agudelo LM, Paulo JD et al. Sjogren keratoconjunctivitis sicca treated with rituximab. Cornea 2007; 26:886-7.
86. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
87. Gonzalez V, Salgueiro E, Jimeno FJ et al. Post-marketing safety of antineoplasic monoclonal antibodies: rituximab and trastuzumab. Pharmacoepidemiol Drug Saf 2008;17: 714-21.
88. Carmona L, Hernandez-Garcia C, Vadillo C et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-9.
89. Doran MF, Crowson CS, Pond GR et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002; 46:2287-93.
90. Falagas ME, Manta KG, Betsi GI et al. Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review. Clin Rheumatol 2007;26: 663-70.
91. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
92. Selenko N, Maidic O, Draxier S et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001;15:1619-26.
93. Byrd JC, Waselenko JK, Maneatis TJ et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791-5.
94. Jensen M, Winkler U, Manzke O et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998;77: 89-91.
95. Bienvenu J, Chvetzoff R, Salles G et al. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2:378-84.
96. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22: 7359-68.
97. Smolen JS, Keystone EC, Emery P et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:143-50.